|
|
|
|
|
|
|
|
|
28.05.26 - 07:33
|
New late-breaking data reinforces IQIRVO®′s impact on ALP, fatigue and pruritus in PBC (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 28 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL) congress. Together, these data further strengthen the growing body of evidence establishing IQIRVO® as the only second-line primary biliary cholangitis (PBC) treatment providing rapid and robust alkaline phosphatase (ALP) reduction with fatigue improvement (in patients with moderate-to-severe fatigue at baseline) and pruritus relief....
|
|
|
|
|
25.05.26 - 18:03
|
GENFIT Highlights Broad Scientific and Strategic Presence at EASL Congress 2026 (GlobeNewswire EN)
|
|
|
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 25, 2026 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights its broad participation at EASL Congress 2026. This visibility reflects both its scientific momentum and its active involvement in the ACLF ecosystem, as well as its position at an inflection point in MASH, while also highlighting the continuous progress made in PBC, driven by its partner Ipsen....
|
|
|
19.05.26 - 21:03
|
Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity (GlobeNewswire EN)
|
|
|
PARIS, FRANCE – 19 MAY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport® (abobotulinumtoxinA) to Botox® (onabotulinumtoxinA) in adults living with upper limb spasticity (ULS)1 will be presented as a late-breaking presentation at the International Society of Physical and Rehabilitation Medicine (ISPRM) world congress in Vancouver on May 19, 2026. The trial showed that patients treated with Dysport had a non-inferior safety profile to Botox and achieved longer-lasting symptom control (based on a pre-specified 80% confidence interval)1....
|
|
|
|
|
|
|
|
|
|
|
|
|
14.05.26 - 07:33
|
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the SCALE Symposium (GlobeNewswire EN)
|
|
|
PARIS, FRANCE, 14 May 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of the Phase II LANTIC trial for the first aesthetic glabellar lines indication with corabotase, a custom-designed molecule recognized as the first in a newly designated class at the SCALE 2026 symposium on May 16, 2026. The Phase I/II trial evaluates the safety and efficacy of corabotase in three aesthetic indications of moderate to severe upper facial lines: glabellar lines, forehead lines and lateral canthal lines....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
